annb0t
Top 20
Kazia Therapeutics Limited (NASDAQ: KZIA) said GBM AGILE, a pivotal study for paxalisib in newly diagnosed glioblastoma, did not meet pre-defined criteria for continuing to a second stage. Patients enrolled in the first stage of the paxalisib arm will continue on treatment as per protocol, and in follow-up, until completion of the final analysis, which Kazia anticipates receiving in 2H of 2023. Given that recruitment is complete, the study will not open to the paxalisib arm in Germany or China. ...
>>> Read more: Kazia Shares Tumble After Update From Pivotal Brain Tumor Trial
>>> Read more: Kazia Shares Tumble After Update From Pivotal Brain Tumor Trial
